St Louis, MONCT05957367Now EnrollingIRB Ready

Gastrointestinal Stromal Tumors Clinical Trial in St Louis, MO

Access cutting-edge gastrointestinal stromal tumors treatment through this phase 1/2 clinical trial at a research site in St Louis. Study-provided care at no cost to qualified participants.

Sponsored by Deciphera Pharmaceuticals, LLC

Quick Self-Assessment

See if you qualify for this St Louis location

Preparing your pre-screening questions…

Expert Care in St Louis

Access gastrointestinal stromal tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gastrointestinal stromal tumors treatment provided free

Apply for This St Louis Location

Check if you qualify for this gastrointestinal stromal tumors clinical trial in St Louis, MO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to St Louis

    Convenient for MO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit St Louis site if eligible
  4. 4Begin participation

About This Gastrointestinal Stromal Tumors Study in St Louis

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.

Sponsor: Deciphera Pharmaceuticals, LLC

Who Can Participate

Inclusion Criteria

Male or female ≥18 years of age
Module A: Part 1 and Part 2: Module A Part 1 and Part 2 inlexisertib combination closed on January 8, 2024, with no participants enrolled.
Module B: Only for Part 1 (Safety/Dose-finding):
Pathologically confirmed diagnosis of GIST with a KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation
Must have progressed on at least one approved systemic regimen given in the locally advanced or metastatic setting or have documented intolerance to it
Must not have received prior ripretinib treatment
Module B: Only for Part 2 (Expansion)
Pathologically confirmed GIST with documented mutation in KIT exon 11
Must have progressed on imatinib given in the locally advanced or metastatic setting or have been intolerant to imatinib and may not have received additional systemic therapy for GIST
Must have at least 1 measurable lesion according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Must have a life expectancy of more than 3 months and an ECOG performance status of 0-1
Adequate organ function and bone marrow reserve based on laboratory assessments performed at Screening
Must provide a fresh tumor biopsy, if able

Exclusion Criteria

Must not have received the following within the specified time periods prior to the first dose of study drug:
Medications, including anticancer therapies, that are known strong or moderate inhibitors or inducers of CYP3A4 or P-glycoprotein (P-gp) including certain herbal medications (eg, St. John's wort): 14 days or 5×the half-life of the medication (whichever is longer)
Other anticancer therapies and any investigational therapies with a known safety and PK profile: 14 days or 5×the half-life of the medication (whichever is shorter)
Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days
Grapefruit or grapefruit juice: 14 days
Have not recovered from all clinically relevant toxicities from prior therapy
New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug
Symptomatic central nervous system (CNS) metastases or presence of leptomeningeal disease
Malabsorption syndrome
Radiation for indications other than bone disease must have been completed 4 weeks prior to first dose of study drug, unless it consisted of limited field palliative radiation, including whole brain radiation, which must have been completed at least 2 weeks prior to first dose of study drug
Major surgery within 4 weeks of the first dose of study drug
Active HIV, Hepatitis B or Hepatitis C infection

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in St Louis?

Yes, this clinical trial (NCT05957367) has an active research site in St Louis, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gastrointestinal Stromal Tumors Treatment Options in St Louis, MO

If you're searching for gastrointestinal stromal tumors treatment options in St Louis, MO, this clinical trial (NCT05957367) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our St Louis research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced gastrointestinal stromal tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gastrointestinal stromal tumors clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in St Louis, MO

See all ankylosing spondylitis clinical trials recruiting in St Louis — not just this study.

Browse Ankylosing Spondylitis Trials in St Louis →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsGeographic Atrophy TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in St Louis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · St Louis, MO